Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease

OSAKA, Japan & SAN DIEGO & SEATTLE–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) and PvP Biologics, Inc. (“PvP”) today announced a global agreement for the development of KumaMax, a novel enzyme designed to break …
( read original story …)


Related Post

Bank of Japan Sticks With Holding Pattern
views 135
TOKYO—The Bank of Japan left its aggressive easing...
Huge cave found on moon, could house astronauts: J...
views 182
Scientists at Japan's space agency have discovered...
Nikkei falls to near 3-month low as firm yen, Nort...
views 203
TOKYO, Aug 14 (Reuters) - Japan's Nikkei share ave...
Black Back For More In Osaka Hai
views 338
Newly promoted to Grade I status, Hanshin’s Osaka ...
Japan puts free early education, drug reform on wi...
views 258
TOKYO -- Free nursery school and kindergarten for ...
Fujitsu, Japanese banks to test blockchain-based m...
views 189
Information and communication technology firm Fuji...
Qatar Airways to deploy A350 on Tokyo Haneda route
views 258
Starting July 1, Qatar Airways will be replacing i...
DENSO to Strengthen R&D Capabilities and Colla...
views 174
DENSO will transfer part of the R&D functions curr...
Japan logs trade deficit in January, as imports ju...
views 165
A man walks on the bridge at Tokyo's Shiodome busi...
Japan city uses emergency system to recall blowfis...
views 209
(Aichi Prefectural Government's Department of Heal...